Brought to you by 
Biologix FZCo. to sell Orexigen's Contrave in the Middle East
26 Jul 2017
Executive Summary
Orexigen Therapeutics Inc. licensed Biologix FZCo. rights to its obesity drug Contrave (naltrexone HCl/bupropion HCl prolonged release) in the Middle East.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biologix FZCo. to sell Orexigen's Contrave in the Middle East
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice